Drug firm, Sun Pharmaceutical Industries Ltd, on Friday (June 13) announced the appointment of Kirti Ganorkar as its new managing director, effective September 1, 2025. The move is part of a planned leadership transition, with Founder Dilip Shanghvi set to continue in his role as executive chairman of the board.
Ganorkar, who will take charge pending shareholder approval at the upcoming annual general meeting, will assume responsibility for the company’s entire business and functional operations. A chemical engineer and MBA, Ganorkar joined Sun Pharma in 1996.
Ganorkar has been heading the company’s India business since June 2019 and has increased its market share steadily. Previously, he had held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation at Sun Pharma.
Also Read: Sun Pharma Q4 Results: Profit misses estimate, revenue up 8% YoY; ₹5.50 dividend announced
He played a key role in driving its foray into specialty by securing rights for innovative products such as Ilumya. Ganorkar led Sun Pharma’s entry into Japan and laid the initial groundwork for the company’s entry into Europe. He supported the US business with stewardship of several notable generic projects from concept to commercialisation.
Ganorkar said, “It has been a profoundly rewarding journey to participate in the company’s transformation into a leading global pharmaceutical enterprise. I’m confident of the continued success of the company.”
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “Kirti has consistently demonstrated effective leadership managing diverse roles at Sun. I have a firm belief in his ability to lead the company into its next phase of growth and extend my best wishes for his success.”
Also Read: Sun Pharma to ramp up specialty play, eyes more acquisitions
As executive chairman, Shanghvi will continue to chair the board and play a role in shaping the company’s long-term strategy.
Shares of Sun Pharmaceutical Industries Ltd ended at ₹1688.70, up by ₹1.70, or 0.10%, on the BSE.
(Edited by : Shoma Bhattacharjee)
